Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has ...

The sNDA submission seeking approval for the Krazati/Erbitux combo therapy to treat the CRC indication is based on positive results from Bristol Myers’ phase I/II KRYSTAL-1 study.

Last year, the FDA approved Bristol Myers Squibb's Krazati to treat colorectal cancer in patients with KRAS mutation. Colorectal cancer, the third most common cancer globally, is also the second ...